Stock Track | Neuren Pharmaceuticals Soars 5.30% Intraday on Positive European Regulatory News for Daybue

Stock Track

Jun 30

Neuren Pharmaceuticals Ltd (NEU.AU) experienced a significant price surge of 5.30% during intraday trading on Tuesday, reflecting strong investor optimism following positive regulatory developments.

The stock movement appears to be driven by news that Neuren is expected to receive royalties from European Daybue sales in the first quarter of fiscal year 2027. This follows a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use regarding Daybue, which is used to treat neurobehavioral symptoms of Rett syndrome in adults and pediatric patients.

Final approval now depends on the European Commission's decision, which is expected in the coming months. Analyst firm Jefferies maintained its buy rating and price target of AU$28 on Neuren Pharmaceuticals, reinforcing positive sentiment around the company's prospects.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1130284797"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1130284797\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1130284797?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-30 08:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1130284797","market":"nz","top_or_hot":-1,"title":"Stock Track | Neuren Pharmaceuticals Soars 5.30% Intraday on Positive European Regulatory News for Daybue","media":"Stock Track","content":"<p>Neuren Pharmaceuticals Ltd (NEU.AU) experienced a significant price surge of 5.30% during intraday trading on Tuesday, reflecting strong investor optimism following positive regulatory developments.</p><p>The stock movement appears to be driven by news that Neuren is expected to receive royalties from European Daybue sales in the first quarter of fiscal year 2027. This follows a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use regarding Daybue, which is used to treat neurobehavioral symptoms of Rett syndrome in adults and pediatric patients.</p><p>Final approval now depends on the European Commission's decision, which is expected in the coming months. Analyst firm Jefferies maintained its buy rating and price target of AU$28 on Neuren Pharmaceuticals, reinforcing positive sentiment around the company's prospects.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Neuren Pharmaceuticals Soars 5.30% Intraday on Positive European Regulatory News for Daybue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Neuren Pharmaceuticals Soars 5.30% Intraday on Positive European Regulatory News for Daybue\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-06-30 08:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Neuren Pharmaceuticals Ltd (NEU.AU) experienced a significant price surge of 5.30% during intraday trading on Tuesday, reflecting strong investor optimism following positive regulatory developments.</p><p>The stock movement appears to be driven by news that Neuren is expected to receive royalties from European Daybue sales in the first quarter of fiscal year 2027. This follows a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use regarding Daybue, which is used to treat neurobehavioral symptoms of Rett syndrome in adults and pediatric patients.</p><p>Final approval now depends on the European Commission's decision, which is expected in the coming months. Analyst firm Jefferies maintained its buy rating and price target of AU$28 on Neuren Pharmaceuticals, reinforcing positive sentiment around the company's prospects.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NEU.AU","symbol_name":"NEUREN PHARMACEUTICALS LTD","start_time":0,"source_url":"","article_id":"1130284797","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1130284797","pubTimestamp":1782777748,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Neuren Pharmaceuticals Ltd (NEU.AU) experienced a significant price surge of 5.30% during intraday trading on Tuesday, reflecting strong investor optimism following positive regulatory...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NEU.AU":"NEUREN PHARMACEUTICALS LTD"},"translate_title":"个股追踪|Neuren Pharmaceuticals盘中大涨5.30%欧洲监管利好Daybue","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NEU.AU":1},"content_text":"Neuren Pharmaceuticals Ltd (NEU.AU) experienced a significant price surge of 5.30% during intraday trading on Tuesday, reflecting strong investor optimism following positive regulatory developments.The stock movement appears to be driven by news that Neuren is expected to receive royalties from European Daybue sales in the first quarter of fiscal year 2027. This follows a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use regarding Daybue, which is used to treat neurobehavioral symptoms of Rett syndrome in adults and pediatric patients.Final approval now depends on the European Commission's decision, which is expected in the coming months. Analyst firm Jefferies maintained its buy rating and price target of AU$28 on Neuren Pharmaceuticals, reinforcing positive sentiment around the company's prospects.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}